Clinical and laboratory predictors of mortality in Staphylococcus aureus bacteremia in a high-risk setting: a single-center retrospective analysis of Pitt score, SOFA, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio

高危人群中金黄色葡萄球菌菌血症死亡率的临床和实验室预测因素:一项单中心回顾性分析,包括Pitt评分、SOFA评分、中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值。

阅读:2

Abstract

OBJECTIVE: Staphylococcus aureus bacteremia (SAB) is associated with significant morbidity and mortality despite advancements in antimicrobial therapies. Timely risk stratification is critical to optimize patient outcomes. This study aimed to evaluate the prognostic value of clinical (Pitt bacteremia score [PBS]), combined clinical and laboratory (Sequential Organ Failure Assessment [SOFA]), and laboratory-based parameters (neutrophil-to-lymphocyte ratio [NLR] and platelet-to-lymphocyte ratio [PLR]) in patients with SAB. METHODS: We conducted a retrospective observational study of 150 adult patients diagnosed with monomicrobial SAB between November 2023 and November 2024 at a tertiary care center. The predictive value of PBS, SOFA, NLR, and PLR for in-hospital mortality was assessed using ROC analysis and logistic regression. RESULTS: The overall in-hospital mortality rate was 46%. PBS >4 and NLR >21 were independently associated with increased mortality (OR 11.72 and 6.36, respectively; p < 0.001). Absence of fever (OR 0.11) and presence of central venous catheter (OR 4.11) were also significant predictors. ROC analysis demonstrated good predictive performance for both PBS (AUC: 0.82) and SOFA (AUC: 0.795) scores with no statistically significant difference between them. Community-acquired SAB and primary bacteremia were associated with worse prognosis. Methicillin resistance did not significantly affect mortality. Fever response was significantly blunted in older adults but not in immunosuppressed patients. CONCLUSION: High PBS and NLR are strong and independent predictors of mortality in SAB. As this study was conducted in a high-risk cohort with a considerable proportion of critically ill and immunocompromised patients, the findings are particularly relevant to this vulnerable population. External validation in larger, multicenter cohorts is required to confirm their generalizability.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。